Last reviewed · How we verify
NCT03588819: 2SMART
Stereotactic MRI-Guided Radiation for Localized Prostate Cancer
NA trial testing SABR in Prostate Cancer in 30 participants. Status unknown.
23 January 2024
Quick facts
| Lead sponsor | Sunnybrook Health Sciences Centre |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 23 April 2018 |
| Primary completion | 23 January 2024 |
| Estimated completion | 23 April 2024 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- SABR
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Sunnybrook Health Sciences Centre — full company profile →
Who can join
18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This single arm, prospective study will determine the prostate-specific quality of life (QOL) of patients undergoing undergoing a 2 fraction MRI-guided stereotactic ablative body radiation (SABR) protocol. We propose prescribing a prostate dose of 26 Gy in 2 fractions and a dose of up to 32 Gy to the dominant intraprostatic lesion (DIL) in 2 fractions over one week.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate Cancer.
Ong WL, Cheung P, Chung H, Chu W, et al · · 2023 · cited 8× · PMID 37419394 · DOI 10.1016/j.ijrobp.2023.06.250 -
Urethra contouring on computed tomography urethrogram versus magnetic resonance imaging for stereotactic body radiotherapy in prostate cancer.
Ong WL, Allan Hupman M, Davidson M, Ruschin M, et al · · 2024 · cited 6× · PMID 38234697 · DOI 10.1016/j.ctro.2023.100722 -
Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer.
Ong WL, Davidson M, Cheung P, Chung H, et al · · 2023 · cited 6× · PMID 37619656 · DOI 10.1016/j.radonc.2023.109864 -
Exploration of an adaptive proton therapy strategy using CBCT with the concept of digital twins.
Chang CW, Tian Z, Qiu RLJ, Scott Mcginnis H, et al · · 2025 · cited 4× · PMID 39761649 · DOI 10.1088/1361-6560/ada684 -
External beam focal boost radiotherapy to intraprostatic lesions in prostate cancer: a scoping review.
Liu Y, Qin S, Ren X, Bai Y, et al · · 2026 · PMID 42093677 · DOI 10.1016/j.phro.2026.100980 -
Comprehensive one-day management of prostate cancer patients: PRO-FAST single-fraction ablative, urethral-sparing, HDR-like, robotic SBRT.
Fodor A, Giannini L, Torrisi M, Brombin C, et al · · 2025 · PMID 40866948 · DOI 10.1186/s13014-025-02713-9
Verify or expand the search:
- PubMed search for NCT03588819
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SABR
Trials testing the same drug.
- NCT06937281 — SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors · NA · not yet recruiting
- NCT06521866 — Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorec · Phase 2 · recruiting
- NCT05311527 — UroLift System With SAbR for Prostate Cancer and BPH · NA · completed
- NCT05377047 — Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer · NA · recruiting
- NCT06613295 — Separation Surgery Followed by Stereotactic Ablative Body Radiotherapy (SABR) Versus SABR Alone for Spinal Metastases · NA · recruiting
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Sunnybrook Health Sciences Centre trials
Trials by the same sponsor.
- NCT07478705 — Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid · NA · not yet recruiting
- NCT07376018 — Ketogenic Diet and Neuromodulation in Treatment Resistant Depression · NA · not yet recruiting
- NCT07350278 — Comparing Virtual Reality Simulation to High Fidelity Simulation as an Educational Modality for Electroconvulsive Therap · NA · not yet recruiting
- NCT07191145 — Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) · Phase 3 · not yet recruiting
- NCT07308587 — Evaluation of Intercostal Neuralgia in Patients With Chest Tube Insertion After Traumatic Rib Fracture · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03588819 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sunnybrook Health Sciences Centre
- Last refreshed: 14 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03588819.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing